目的：探讨血浆中长链非编码RNA转移相关肺腺癌转录因子1(MALAT1)对肺癌临床诊断意义。方法分别检测84例肺癌患者(34例腺癌、26例鳞癌、24例小细胞性肺癌)和60例体检健康者血浆中MALAT1、癌胚抗原(CEA)、CK19片段(CYFRA21-1)、鳞状细胞癌抗原(SCC-Ag)和神经元特异性烯醇化酶( NSE)的表达水平,通过logistic 回归分析和受试者工作曲线( ROC曲线)分析其灵敏度、特异度等指标。结果 MALAT-1在肺癌患者血浆中比健康对照组的表达水平高( P<0．01)；当临界点( cutoff 值)为0．03时, MALAT-1在腺癌中阳性率为70．59%,其诊断肺癌时AUC、灵敏度和特异度分别为0．70、58．33%、81．67%。MALAT-1、NSE 和CYFRA21-1三者联合检测肺癌及小细胞性肺癌的 AUC 分别为0．91、0．98,灵敏度分别为82．14%、95．83%,特异度分别为85．00%、93．33%。 MALAT-1在腺癌中 AUC、灵敏度和特异度分别为0．81、76．47%、83．33%。结论 MALAT-1可作为肺癌,特别是肺腺癌血清学诊断独立标志物,MALAT-1、NSE 和CYFRA21-1三指标联合可显著提高肺癌及不同肺癌病理类型的诊断效能。“,”Objective To explore diagnostic value of long non-coding RNA metastasis-associated lung ade-nocarcinoma transcript 1 (MALAT1) in serum for clinical diagnosis of lung cancer. Methods Serum MALAT1, CEA ( Carcinoembryonic antigen) , CYFRA21-1 ( cytokeratin 19 fragments) , SCC-Ag ( Squamous cell carcinoma an-tigen) and NSE (neuron specific enolase) levels were detected in 84 lung cancer cases (34 adenocarcinoma carcino-ma, 26 squamous carcinoma cases, 24 small cell lung cancer cases) and 60 healthy people. The related indexes, such as sensitivity and specificity, were analyzed by logistic regression and ROC curves. Results The serum MAL-AT-1 level in lung cancer cases were obviously higher than in healthy controls (P<0. 01). When the cutoff point was 0. 03, the positive rate of MALAT-1 was 70. 95%, and the area under the ROC curve (AUC) of MALAT-1 in lung cancer were 0. 70, and the sensitivity and specificity were 58. 33% and 81. 67%, respectively. The AUC of the com-bined determination of MALAT-1, NSE and CYFRA21-1 in lung cancer and small cell lung cancer cases were 0. 91 and 0. 98, respectively. The sensitivity was 82. 14% and 95. 83%, and the specificity was 85. 00% and 93. 33% re-spectively. The AUC, sensitivity, and specificity of MALAT-1 in adenocarcinoma were 0. 81, 76. 47%, and 83. 33%, respectively. Conclusion MALAT-1 can be regarded as an independent serological diagnostic tumor marker of lung cancer, especially lung adenocarcinoma. The combined determination of MALAT-1, NSE and CY-FRA21-1 can significantly increase the diagnosis effects of lung cancer and different pathological types of lung cancer.